CYCLOSPORINE-ASSOCIATED CHRONIC NEPHROPATHY
CYCLOSPORINE-ASSOCIATED CHRONIC NEPHROPATHY
复制标题
DOI:
10.1056/nejm198409133111103
复制
发表时间:
1984-01-01
影响因子:
158.5
通讯作者:
PERLROTH, M
中科院分区:
文献类型:
--
作者:
MYERS, BD;ROSS, J;PERLROTH, M
Glomerular filtration in 17 recipients of heart transplants who were treated for 12 mo. or longer with cyclosporine (cyclosporin A) was evaluated. The control group consisted of 15 heart-transplant recipients who were treated with azathioprine and who had also survived for at least 12 mo. Despite an equivalent cardiac output, the glomerular filtration rate was depressed (51 .+-. 4 vs. 93 .+-. 3 ml/min, P < 0.005) in transplant recipients treated with cyclosporine. Cyclosporine treatment was also associated with reduced renal plasma flow (320 .+-. 21 vs. 480 .+-. 30 ml/min, P < 0.001). A trend toward restricted transglomerular transport of neutral dextrans (radii, 2.4-5.8 nm) in cyclosporine-treated recipients suggested an intrinsic loss of ultrafiltration capacity by glomerular capillaries rather than a hemodynamic basis for the reduced glomerular filtration rate. Histopathologic examination of the kidneys of 5 cyclosporine-treated patients with glomerular hypofiltration revealed a variable degree of tubulointerstitial injury accompanied by focal glomerular sclerosis. Among the 32 heart-transplant recipients treated for more than 12 mo. with cyclosporine, end-stage renal failure developed in 2. Long-term cyclosporine therapy may lead to irreversible and potentially progressive nephropathy. Cyclosporine should be used with restraint and caution until ways are found to mitigate its nephrotoxicity.